Assessment of intracranial metastases from neuroendocrine tumors/carcinoma

Ahmad M. Ragab Shalaby, Hoshi Kazuei, Honma Koichi, Saeed Naguib, Lubna A. Al-Menaweii

Department of Oncology-Pathology, Kameda Hospital and Oncology Center, Kamogawa Chiba, Japan; 1Department of Immunology, Damanhour National Medical Institute, Damanhour, Egypt; 2Department of Pathology, KAAZ Hospital and Oncology Center, Jeddah, Saudi Arabia

ABSTRACT

Background: The most common sites of origin for neuroendocrine carcinoma are gastrointestinal tract and its accessory glands, and lungs. Materials and Methods: One-hundred fifty cases diagnosed with metastatic brain lesions were retrieved from hospital records within 5 years. For these cases, the primary neoplasm, histopathological classification, metastasis, treatment, and fate all were studied. Results: Intracranial deposits were detected in 10%. The primary lesion was in the lungs in 87% of patients, and 1 patient in the breast and 1 in esophagus. Pathological classification of the primary lesion was Grade 2 (MIB-1: 3–20%) in 1 patient and neuroendocrine carcinoma (MIB-1: ≥21%) in 14 patients. The median period from onset of the primary lesion up to diagnosis of brain metastasis was 12.8 months. About 33% of patients had a single metastasis whereas 67% patients had multiple metastases. Brain metastasis was extirpated in 33% of patients. Stereotactic radiotherapy alone was administered in 20% of patients, and brain metastasis was favorably controlled in most of the patients with coadministration of cranial irradiation as appropriate. The median survival period from diagnosis of brain metastasis was 8.1 months. Conclusion: Most of patients with brain metastasis from neuroendocrine carcinoma showed the primary lesion in the lungs, and they had multiple metastases to the liver, lymph nodes, bones, and so forth at the time of diagnosis of brain metastasis. The guidelines for accurate diagnosis and treatment of neuroendocrine carcinoma should be immediately established based on further analyses of those patients with brain metastasis.

Key words: Intracranial metastases, neuroendocrine carcinoma, radiotherapy

Introduction

Neuroendocrine tumor (NET)/carcinoma is characterized by secretion of many active hormones and the presence of intracytoplasmic secretory granules.[1]

They may develop in all body organs, and many of them also have a malignant course. The World Health Organization (WHO) therefore attempted to grade NETs based on systematic clinical pathological classification, but classifications with different criteria were proposed for NETs originating from the favored sites (pancreas and gastrointestinal tract) and NETs originating from the lungs.

Neurosurgeons are increasingly experiencing patients with brain metastasis from tumors diagnosed as neuroendocrine carcinoma.[2,3] However, few reports examined brain metastasis of such patients.

Materials and Methods

All cases of neuroendocrine carcinoma were searched among histopathological diagnoses of all neoplasm specimens obtained during surgical procedures at Kameda Hospital and Oncology Center; Kamogawa - Japan during the 5 years between January 2011 and December 2015. As a result, 150 patients were confirmed
carrying their diagnosis. The age of patients ranged between 21 and 91 years (median: 64.5-year-old) and there were 90 men and 60 women. The primary site of NETs was the lungs in 51 patients, rectum in 18 patients, pancreas in 13 patients, stomach in 10 patients, mammary glands in 10 patients, uterus in 9 patients, lymph nodes in 8 patients, and duodenum in 6 patients. Other sites of onset were the thymus gland in 4 patients, esophagus in 3 patients, ileum in 3 patients, liver in 2 patients, colon in 2 patients, pharynx in 2 patients, paranasal sinus in 1 patient, kidneys in 1 patient, urinary tract in 1 patient, and ovaries in 1 patient and 5 cases of unknown primary.

This study was conducted in Kameda Hospital and Oncology Center; Kamogawa-Chiba-JAPAN.

Results

Clinical data
Age of patients ranged between 34 and 78 years (median: 68-year-old) and 20 of them were men and 10 of them were women [Table 1].

The period from histopathological detection of primary lesion up to diagnosis of brain metastasis ranged between 0 and 33.4 months (median: 12.8 months) [Figure 1].

Fate and outcomes
The follow-up period after treatment of metastatic brain tumors was from 1 to 34 months (median: 5.8 months), and 29 of 31 patients were deceased by the time of completion of examinations. Analysis by the Kaplan–Meier survival curve revealed a median survival period of 8.1 months [Figure 2-5].

Discussion

Carcinoid has been the description of NETs for any years. It was later considered that NETs should be treated as clinically malignant tumors and the term “carcinoid” was eliminated from the WHO classification in 2000. Subsequently, NETs were categorized into five types, namely, NET Grade 1, NET Grade 2, NEC (large cell or small cell), mixed adenoneuroendocrine carcinoma, and hyperplastic and neoplastic lesions, in the 2010 WHO classification according to the grading by the Ki-67 labeling index.[8]

The incidence of NETs among all tumors was 4.44% in Caucasians and 6.5% in African Americans, and male patients were slightly predominant; the incidence increased by 37% in Caucasians and 40% in African Americans compared with the statistical data between 1993 and 1997.[9] The site of onset of NETs in Caucasian patients was the lungs/bronchus in 31.9%, small intestine in 17.7%, unknown in 13.5%, and rectum in 12.3% whereas that in African American patients was the rectum in 27%, small intestine in 21%, and

| Table 1: Clinical, Pathological, Imaging and Therapeutic Data |
|---------------------------------|----------------|
| Neuroendocrine tumors           | 150           |
| Brain metastasis (%)            | 15 (10)       |
| Age                             | 34-78 (median: 68) |
| Gender                          |               |
| Male                            | 20            |
| Female                          | 10            |
| Origin                          |               |
| Lung (%)                        | 13 (87)       |
| Breast                          | 1             |
| Esophagus                       | 1             |
| Pathology (%)                   |               |
| LCNEC                           | 5 (33)        |
| Small cell carcinoma            | 6 (40)        |
| Carcinoma with neuroendocrine differentiation | 4 (27) |
| Grade (MIB-1) (%)               |               |
| 2 (3-20)                        | 1             |
| 3 (≥21)                         | 14 (90.3)     |
| Imaging                         |               |
| Single/nodular type             | 3             |
| Single/cystic type              | 2             |
| Multiple/nodular type           | 5             |
| Multiple/cystic type            | 1             |
| Multiple/nodular and cystic type| 4             |
| Treatment modalities            |               |
| Surgery                         | 1             |
| Surgery + WBRT                  | 3             |
| Surgery + GK                    | 1             |
| Surgery + WBRT + GK             | 1             |
| WBRT                            | 3             |
| GK                              | 3             |
| WBRT + GK                       | 1             |
| Chemotherapy                    | 1             |
| Best supportive care            | 1             |

n: Number, LCNEC: Large cell neuroendocrine carcinoma, WBRT: Whole brain radiotherapy, GK: Gamma knife.

Figure 1: Period from histopathological diagnosis of the primary tumor till discovery of intracranial deposits.
lungs/bronchus in 18.3%. Thus, a slight ethnic difference was observed.\[^9\]\[^9\] Also, in the percentage of NETs against all types of tumors in each site of origin, NETs accounted for the highest (1.42%) in the lungs/bronchus in Caucasian patients whereas NETs accounted for the highest (1.65%) in the rectum in African American patients.\[^9\]\[^9\] The pancreas accounted for 4% of all types of the NETs and for approximately 0.3% of all pancreatic cancers,\[^9\] being a very rare disease. Regarding the metastasis of NETs to other organs, distant metastasis was observed in 20–30% of patients at the time of diagnosis.

We retrieved 150 patients with NETs who were diagnosed at our hospital over the past 5 years. The site of onset was the lungs in 51 patients, rectum in 18 patients, and pancreas in 13 patients, which were almost comparable with the site of onset in Caucasian patients, and the number of patients with NETs in the pancreas was higher in Japanese patients. Brain metastasis was observed in 15 patients (10.0%) and it was interesting that 13 (87%) of them were metastasis from the primary lung NETs. Primary brain metastasis is mainly caused by primary lung NETs.

The European Neuroendocrine Tumor Society (ENETS) in 2012 published the consensus guidelines for the diagnosis and treatment of NETs for each site of onset.\[^10\]\[^10\] During preparation of the guidelines, the ENETS advisory board, and experts have published the analytical results on metastasis to other organs from NETs.\[^10\]\[^13\]\[^10\] The description of brain, and ovarian metastasis in the article stated that brain metastasis from primary lung NETs accounted for 45–71% of patients with the median period of 1.5 years from the diagnosis of the primary lesion until confirmation of brain metastasis.\[^8\]\[^8\] Lymph node metastasis and liver metastasis were present in 75% and 50% of the patients with brain metastasis,\[^11\]\[^11\] respectively, which were comparable to the results of our present study. Approximately 1.4% of metastatic brain tumors were NETs whereas the incidence of brain metastasis from NETs was 1.5–5%.\[^11\]\[^11\] The incidence of primary lung NETs was higher in our present study and that would be the cause of slightly higher incidence in brain metastasis at 10.3%. A report that summarized 24 patients was the highest number of patients and only 57 patients were reported during the 46 years between 1962 and 2007.\[^11\]\[^11\] The report of ENET\[^11\]\[^11\] did not contain a definite description of pathological findings and grading.

When limited to lung NETs, brain metastasis occurs in 30% or more of the large cell neuroendocrine carcinoma (LCNEC) patients and in 24% of the small cell carcinoma patients.\[^3\]\[^12\]\[^3\] In the present study, the strategy of surgery and radiotherapy for the patients was determined based on the symptoms, PS, and imaging findings (number of brain metastases), and such action would be the standard concept for metastatic brain tumors at present. On the other hand, prophylactic cranial irradiation is also a possible option for small cell lung cancer.\[^3\]\[^12\]\[^14\]\[^3\] The median survival period from diagnosis of brain metastasis was 8.1 months in the present study, and it

---

**Figure 2:** Radiologic patterns. (a) Single/nodular type. (b) Single/cystic type. (c) Multiple/nodular type. (d) Multiple/cystic type

**Figure 3:** Survival period after diagnosis of metastatic brain tumor
was not greatly different from that of brain metastasis in all lung cancer patients. Lately, various therapies such as combination chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors, and angiogenesis inhibitors have become available for brain metastasis originating from lung cancer.
Conclusion

Approximately 10% of NET patients developed brain metastasis at slightly longer than 1 year after diagnosis, and metastasis originating from LCNEC or small cell carcinoma occurred in most of them. The treatment options for brain metastasis varied depending on the symptoms due to brain metastasis, performance status, and metastatic images. Most of the metastases were controlled by applying active therapy to the brain lesion, but the mean survival period was 8 months from diagnosis of brain metastasis, mainly because of aggravation of the primary lesion or metastasis to other organs. Standardization of clinical and pathological interpretation of NETs can give better help by establishment of optimal guidelines for diagnosis and treatment of brain metastasis originating from NETs.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References

1. Oberndorfer S. Karzinoide tumoren des dünnarms. Frankfurt Z Pathol 1907;1:425-9.
2. Mallory GW, Fang S, Giannini C, Van Gompel JJ, Parney IF. Brain carcinoid metastases: Outcomes and prognostic factors. J Neurosurg 2013;118:889-95.
3. Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer 2012;77:365-70.
4. Terada T. Pulmonary large cell neuroendocrine carcinoma diagnosed in a brain metastasis. Int J Clin Exp Pathol 2012;5:159-62.
5. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. Second cancers in patients with neuroendocrine tumors. PLoS One 2013;8:e86414.
6. Tsagu A, Yoshiyama M, Matsumae M. Brain metastasis from large cell neuroendocrine carcinoma of the urinary bladder. Surg Neurol Int 2011;2:94.
7. Zeicheck SB, Cusmir M, Francoilla M, Hirzel A. Typical bronchial carcinoid metastasizing to the brain: A case presentation. Case Rep Oncol 2011;4:602-10.
8. Vinik AI, Woltering EA, Warner RR, Caplin M, O’Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-34.
9. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drodal I, Chan AK, et al. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 2008;113:2655-64.
10. European Neuroendocrine Tumor Society. Available from: http://www.enets.org. [Last accessed on 2015 Feb 12].
11. Pavel M, Grossman A, Arnold R, Perren A, Kaltas S, Steinmuller T, et al. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology 2010;91:326-32.
12. Kim SJ, Kim JW, Han SW, Oh DY, Lee SH, Kim DW, et al. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: Tumor grade and metastatic site are important for treatment strategy. BMC Cancer 2010;10:448.
13. Chi A, Komaki R. Treatment of brain metastasis from lung cancer. Cancers (Basel) 2010;2:2100-37.
14. Akimoto J, Fukuhara H, Suda T, Nagai K, Ichikawa M, Fukami S, et al. Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain. BMC Cancer 2016;16:36.
15. D’Antonio C, Passaro A, Gori B, Del Signore F, Migliorino MR, Recchiardi S, et al. Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies. Ther Adv Med Oncol 2014;6:101-14.